Respiratory Syncytial Virus (RSV) : Maternal and Infant protection program
-
RSV maternal vaccination program: A single dose of maternal RSV vaccine Abrysvo® provided to people from 28 weeks of pregnancy to pass immunity to their infant, funded under the National Immunisation Program (NIP), commenced on 3 February 2025.
-
RSV infant immunisation program: A dose of Beyfortus™ monoclonal antibody immunisation, available between 1 April 2025 and 30 September 2025, to eligible infants born during or entering their first RSV season, and infants less than 2 years of age who remain at risk of severe RSV disease through their second RSV season.
RSV maternal protection program (Abrysvo)
- National Immunisation Program – South Australian Schedule: February 2025 (PDF 64KB)
- RSV products – Program advice for health professionals (Department of Health and Aged Care)
Source: Department of Health and Aged Care
RSV infant protection program (Beyfortus)
- RSV Immunisation Provider Training and Education Course
- Funded RSV Monoclonal Antibody: Infant Protection Program - South Australia Schedule (PDF 298KB)
- RSV Monoclonal Antibody: Infant Protection Program - Guide for Health Professionals (PDF 286KB)
Clinical guidance
- See the Australian Immunisation Handbook RSV chapter and Flowchart for more information on RSV immunisation recommendations in infants and children.
- See conditions associated with increased risk of severe RSV disease in infants and young children.
- National Centre for Immunisation Research and Surveillance - RSV FAQs (NCIRS)